EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

A Randomized Controlled Trial of a Biodegradable Polymer, Microcrystalline Sirolimus-Eluting Stent (MiStent) versus Another Biodegradable Polymer Sirolimus-Eluting Stent (TIVOLI): The DESSOLVE-C Trial

Bin Wang, Sicong Ma, Zhiyong Wang, Li Zhang, Hanjun Pei, Yang Zheng, Yuejin Yang, Zheng Zhang, Xinqun Hu, Ziwen Ren, Feng Zhang, Changqian Wang und 11 weitere

Cardiology Discovery · 2023

DOI: 10.1097/cd9.0000000000000067 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cardiology Discovery, 2023. Verfasst von Bin Wang und 22 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Data comparing the outcomes of MiStent (Micell Technologies, Durham, North Carolina, USA) microcrystalline biodegradable polymer (BP) drug-eluting stent (DES) and those of another post-marketing BP-DES, TIVOLI (EssenTech, Beijing, China) are rare. This study sought to compare the angiographic efficacy and clinical outcomes of the microcrystalline BP sirolimus-eluting stent (SES) system MiStent and those of TIVOLI BP-SES.

Methods

The DESSOLVE-C trial was a prospective, single-blinded, multicenter, randomized trial (NCT02448524), which randomly assigned patients with de novo coronary lesions to receive MiStent or TIVOLI BP-SES by a 1:1 ratio. The primary endpoint was a non-inferiority comparison of in-stent late lumen loss (LLL) by quantitative coronary angiography at 9 months. The secondary endpoint was device-related clinical cardiovascular composite events (target lesion failure (TLF), composite of cardiac death, target vessel myocardial infarction (MI), and clinically driven target lesion revascularization) and 1-year outcomes.

Results

A total of 428 patients (216 patients in the MiStent group and 212 patients in the TIVOLI group) were enrolled and included in an intention-to-treat analysis. MiStent was not only non-inferior but superior to TIVOLI for in-stent LLL at 9 months ((0.23 ± 0.37) mm vs. (0.34 ± 0.48) mm, P for non-inferiority

Zitieren

APA

Wang, B., Ma, S., Wang, Z., Zhang, L., Pei, H., Zheng, Y., Yang, Y., Zhang, Z., Hu, X., Ren, Z., Zhang, F., Wang, C., Yang, R., Yang, Z., Wang, Y., Fu, G., Cao, Y., Yuan, Z., Xu, K., …, & Jing, Q. (2023). A Randomized Controlled Trial of a Biodegradable Polymer, Microcrystalline Sirolimus-Eluting Stent (MiStent) versus Another Biodegradable Polymer Sirolimus-Eluting Stent (TIVOLI): The DESSOLVE-C Trial. Cardiology Discovery. https://doi.org/10.1097/cd9.0000000000000067

Vancouver

Wang B, Ma S, Wang Z, Zhang L, Pei H, Zheng Y, et al. A Randomized Controlled Trial of a Biodegradable Polymer, Microcrystalline Sirolimus-Eluting Stent (MiStent) versus Another Biodegradable Polymer Sirolimus-Eluting Stent (TIVOLI): The DESSOLVE-C Trial. Cardiology Discovery. 2023. doi:10.1097/cd9.0000000000000067

BibTeX
@article{Wang2023,
  author = {Wang, Bin and Ma, Sicong and Wang, Zhiyong and Zhang, Li and Pei, Hanjun and Zheng, Yang and Yang, Yuejin and Zhang, Zheng and Hu, Xinqun and Ren, Ziwen and Zhang, Feng and Wang, Changqian and Yang, Renqiang and Yang, Zhiming and Wang, Yuexi and Fu, Guosheng and Cao, Yu and Yuan, Zuyi and Xu, Kai and Zhao, Xin and Xu, Bo and Qiu, Miaohan and Jing, Quanmin},
  title = {A Randomized Controlled Trial of a Biodegradable Polymer, Microcrystalline Sirolimus-Eluting Stent (MiStent) versus Another Biodegradable Polymer Sirolimus-Eluting Stent (TIVOLI): The DESSOLVE-C Trial},
  journal = {Cardiology Discovery},
  year = {2023},
  doi = {10.1097/cd9.0000000000000067}
}
Kostenlos starten →